270 related articles for article (PubMed ID: 23824742)
1. Novel small-molecule inhibitors of Bcl-XL to treat lung cancer.
Park D; Magis AT; Li R; Owonikoko TK; Sica GL; Sun SY; Ramalingam SS; Khuri FR; Curran WJ; Deng X
Cancer Res; 2013 Sep; 73(17):5485-96. PubMed ID: 23824742
[TBL] [Abstract][Full Text] [Related]
2. Bcl-2 is a better ABT-737 target than Bcl-xL or Bcl-w and only Noxa overcomes resistance mediated by Mcl-1, Bfl-1, or Bcl-B.
Rooswinkel RW; van de Kooij B; Verheij M; Borst J
Cell Death Dis; 2012 Aug; 3(8):e366. PubMed ID: 22875003
[TBL] [Abstract][Full Text] [Related]
3. Mcl-1 down-regulation potentiates ABT-737 lethality by cooperatively inducing Bak activation and Bax translocation.
Chen S; Dai Y; Harada H; Dent P; Grant S
Cancer Res; 2007 Jan; 67(2):782-91. PubMed ID: 17234790
[TBL] [Abstract][Full Text] [Related]
4. Dual inhibition of Bcl-2 and Bcl-xL strikingly enhances PI3K inhibition-induced apoptosis in human myeloid leukemia cells through a GSK3- and Bim-dependent mechanism.
Rahmani M; Aust MM; Attkisson E; Williams DC; Ferreira-Gonzalez A; Grant S
Cancer Res; 2013 Feb; 73(4):1340-51. PubMed ID: 23243017
[TBL] [Abstract][Full Text] [Related]
5. Co-administration of the mTORC1/TORC2 inhibitor INK128 and the Bcl-2/Bcl-xL antagonist ABT-737 kills human myeloid leukemia cells through Mcl-1 down-regulation and AKT inactivation.
Rahmani M; Aust MM; Hawkins E; Parker RE; Ross M; Kmieciak M; Reshko LB; Rizzo KA; Dumur CI; Ferreira-Gonzalez A; Grant S
Haematologica; 2015 Dec; 100(12):1553-63. PubMed ID: 26452980
[TBL] [Abstract][Full Text] [Related]
6. 'Seed' analysis of off-target siRNAs reveals an essential role of Mcl-1 in resistance to the small-molecule Bcl-2/Bcl-XL inhibitor ABT-737.
Lin X; Morgan-Lappe S; Huang X; Li L; Zakula DM; Vernetti LA; Fesik SW; Shen Y
Oncogene; 2007 Jun; 26(27):3972-9. PubMed ID: 17173063
[TBL] [Abstract][Full Text] [Related]
7. Mcl-1 and Bcl-x
Hockings C; Alsop AE; Fennell SC; Lee EF; Fairlie WD; Dewson G; Kluck RM
Cell Death Differ; 2018 Mar; 25(4):721-734. PubMed ID: 29459767
[TBL] [Abstract][Full Text] [Related]
8. Induction of Noxa sensitizes human colorectal cancer cells expressing Mcl-1 to the small-molecule Bcl-2/Bcl-xL inhibitor, ABT-737.
Okumura K; Huang S; Sinicrope FA
Clin Cancer Res; 2008 Dec; 14(24):8132-42. PubMed ID: 19088028
[TBL] [Abstract][Full Text] [Related]
9. Efficient elimination of cancer cells by deoxyglucose-ABT-263/737 combination therapy.
Yamaguchi R; Janssen E; Perkins G; Ellisman M; Kitada S; Reed JC
PLoS One; 2011; 6(9):e24102. PubMed ID: 21949692
[TBL] [Abstract][Full Text] [Related]
10. Mcl-1 and Bcl-xL regulate Bak/Bax-dependent apoptosis of the megakaryocytic lineage at multistages.
Kodama T; Hikita H; Kawaguchi T; Shigekawa M; Shimizu S; Hayashi Y; Li W; Miyagi T; Hosui A; Tatsumi T; Kanto T; Hiramatsu N; Kiyomizu K; Tadokoro S; Tomiyama Y; Hayashi N; Takehara T
Cell Death Differ; 2012 Nov; 19(11):1856-69. PubMed ID: 22790873
[TBL] [Abstract][Full Text] [Related]
11. ABT-737 reverses the acquired radioresistance of breast cancer cells by targeting Bcl-2 and Bcl-xL.
Li JY; Li YY; Jin W; Yang Q; Shao ZM; Tian XS
J Exp Clin Cancer Res; 2012 Dec; 31(1):102. PubMed ID: 23259599
[TBL] [Abstract][Full Text] [Related]
12. Discovery of Small Molecule Bak Activator for Lung Cancer Therapy.
Park D; Anisuzzaman ASM; Magis AT; Chen G; Xie M; Zhang G; Behera M; Sica GL; Ramalingam SS; Owonikoko TK; Deng X
Theranostics; 2021; 11(17):8500-8516. PubMed ID: 34373755
[No Abstract] [Full Text] [Related]
13. The Bcl-xL inhibitor, ABT-737, efficiently induces apoptosis and suppresses growth of hepatoma cells in combination with sorafenib.
Hikita H; Takehara T; Shimizu S; Kodama T; Shigekawa M; Iwase K; Hosui A; Miyagi T; Tatsumi T; Ishida H; Li W; Kanto T; Hiramatsu N; Hayashi N
Hepatology; 2010 Oct; 52(4):1310-21. PubMed ID: 20799354
[TBL] [Abstract][Full Text] [Related]
14. γ-Secretase inhibition promotes cell death, Noxa upregulation, and sensitization to BH3 mimetic ABT-737 in human breast cancer cells.
Séveno C; Loussouarn D; Bréchet S; Campone M; Juin P; Barillé-Nion S
Breast Cancer Res; 2012 Jun; 14(3):R96. PubMed ID: 22703841
[TBL] [Abstract][Full Text] [Related]
15. BH3-only protein bid participates in the Bcl-2 network in healthy liver cells.
Hikita H; Takehara T; Kodama T; Shimizu S; Hosui A; Miyagi T; Tatsumi T; Ishida H; Ohkawa K; Li W; Kanto T; Hiramatsu N; Hennighausen L; Yin XM; Hayashi N
Hepatology; 2009 Dec; 50(6):1972-80. PubMed ID: 19839062
[TBL] [Abstract][Full Text] [Related]
16. Drp1 is dispensable for apoptotic cytochrome c release in primed MCF10A and fibroblast cells but affects Bcl-2 antagonist-induced respiratory changes.
Clerc P; Ge SX; Hwang H; Waddell J; Roelofs BA; Karbowski M; Sesaki H; Polster BM
Br J Pharmacol; 2014 Apr; 171(8):1988-99. PubMed ID: 24206264
[TBL] [Abstract][Full Text] [Related]
17. Bcl-xL inhibition by molecular-targeting drugs sensitizes human pancreatic cancer cells to TRAIL.
Hari Y; Harashima N; Tajima Y; Harada M
Oncotarget; 2015 Dec; 6(39):41902-15. PubMed ID: 26506422
[TBL] [Abstract][Full Text] [Related]
18. Clitocine induces apoptosis and enhances the lethality of ABT-737 in human colon cancer cells by disrupting the interaction of Mcl-1 and Bak.
Sun JG; Xiang J; Zeng XL; Li X; Wu P; Fung KP; Liu FY
Cancer Lett; 2014 Dec; 355(2):253-63. PubMed ID: 25304383
[TBL] [Abstract][Full Text] [Related]
19. Bcl-2/Bcl-xL inhibitor ABT-263 overcomes hypoxia-driven radioresistence and improves radiotherapy.
Ritter V; Krautter F; Klein D; Jendrossek V; Rudner J
Cell Death Dis; 2021 Jul; 12(7):694. PubMed ID: 34257274
[TBL] [Abstract][Full Text] [Related]
20. Prosurvival Bcl-2 family members affect autophagy only indirectly, by inhibiting Bax and Bak.
Lindqvist LM; Heinlein M; Huang DC; Vaux DL
Proc Natl Acad Sci U S A; 2014 Jun; 111(23):8512-7. PubMed ID: 24912196
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
